Emirates International Investment Co. has acquired a minority stake in Joe & the Juice in a transaction valuing the General Atlantic -backed company at $1.8 billion, according to people familiar with the matter. General Atlantic will remain the majority shareholder in the Danish juice, coffee and sandwich chain, the people said, asking not to be identified because the information isn’t public. EII...
Emirates International Investment Co. has acquired a minority stake in Joe & the Juice in a transaction valuing the General Atlantic -backed company at $1.8 billion, according to people familiar with the matter. General Atlantic will remain the majority shareholder in the Danish juice, coffee and sandwich chain, the people said, asking not to be identified because the information isn’t public. EIIC is acquiring some of General Atlantic’s holding as well as getting new shares, the people said. Representatives for EIIC, which is the investment arm of National Holding Group, and General Atlantic declined to comment. Read More: Joe & The Juice Enters Middle East Market Ahead of IPO, CEO Says General Atlantic had been exploring a possible US initial public offering for Joe & the Juice last year, people familiar with the considerations said at the time . The private equity firm first invested in the business in 2016 and agreed to acquire a majority stake in 2023 from Valedo Partners. Joe & the Juice was founded in Copenhagen in 2002. The company’s revenue reached about $500 million last year, when it opened 75 new stores, including franchises in markets such as Mexico, Morocco and Turkey, the people said. A National Holding affiliate is already a Joe & the Juice franchise partner, including in Spain and Turkey, the people said. The fresh backing is aimed at helping the chain reach a goal of 1,000 stores by 2028, they added. EIIC invests in the Middle East and elsewhere, backing companies such as grocery store operator Spinneys, Lulu Retail, delivery app talabat, cryptocurrency exchange Kraken, Voyager Space and Elon Musk’s xAI Corp.
Sundry Photography/iStock Editorial via Getty Images Shares of Abbott Laboratories ( ABT ) dipped in the premarket on Thursday after the MedTech giant lowered its full-year earnings outlook, indicating an impact from its recent acquisition of cancer diagnostics company Exact Sciences. Compared to $5.55-$5.80 previously and $5.47 in the consensus, the Illinois-based company now projects its 2026 ad...
Sundry Photography/iStock Editorial via Getty Images Shares of Abbott Laboratories ( ABT ) dipped in the premarket on Thursday after the MedTech giant lowered its full-year earnings outlook, indicating an impact from its recent acquisition of cancer diagnostics company Exact Sciences. Compared to $5.55-$5.80 previously and $5.47 in the consensus, the Illinois-based company now projects its 2026 adjusted diluted earnings per share to reach $5.38-$5.58, including $0.20 per share dilution attributed to the $21B deal. "The acquisition of Exact Sciences adds another high-growth business to the Abbott portfolio, further strengthening our confidence in delivering accelerating growth as we move through the year,” CEO Robert Ford said ahead of the earnings call at 9 a.m. ET. However, Abbott’s ( ABT ) top line exceeded Street forecasts for the first time in two quarters, as revenue for Q1 2026 grew ~8% YoY to $11.2B, beating the consensus by $160M, thanks mainly to its Medical Devices division. Meanwhile, its Nutrition segment continued to underperform, adding $2.0B to the topline with a ~6% YoY decline amid lower sales volumes and strategic pricing actions, which the company said will help it improve volume growth for the rest of the year. ABT's MedTech unit added $5.5B in sales with a ~13% YoY growth, and its Diagnostics business generated $2.2B with a ~6% YoY growth as sales from Cancer Diagnostics reflected the acquisition of Exact Sciences. As for the bottom line, ABT’s adjusted EPS improved ~6% YoY to $1.15, while its gross margin reached ~56% from ~57% in the prior year period on an adjusted basis. The company projected its non-GAAP diluted EPS to reach $1.25–$1.31 in Q2, below the consensus of $1.32, and comparable sales growth for 2026 to stand at 6.5%–7.5% compared to 3.7% in Q1. More on Abbott Laboratories Abbott Laboratories: A Dividend Aristocrat With A Compelling Valuation And Return Potential Abbott: A Brighter Investment Case Heading Into Q1 Earnings (Rating U...
Siemens and Humanoid today announced a landmark milestone in the journey to bring physical AI from vision to industrial reality. Humanoid's HMND 01 wheeled Alpha humanoid robot, built using the NVIDIA physical AI stack, has been successfully tested in operations at Siemens' electronics factory in Erlangen, Germany, performing autonomous logistics tasks. This builds on the Siemens and NVIDIA strate...
Siemens and Humanoid today announced a landmark milestone in the journey to bring physical AI from vision to industrial reality. Humanoid's HMND 01 wheeled Alpha humanoid robot, built using the NVIDIA physical AI stack, has been successfully tested in operations at Siemens' electronics factory in Erlangen, Germany, performing autonomous logistics tasks. This builds on the Siemens and NVIDIA strategic partnership, announced at CES, to build the world's first fully AI-driven, adaptive manufacturin
Most people searching for the next great retirement compounder go straight to the obvious names that are hot today: Nvidia , Microsoft , Meta . That's understandable. But the stocks that actually change lives over 20 or 30 years tend to be the ones nobody was talking about at the starting line. Right now, SoundHound AI (NASDAQ: SOUN) is one of the quieter names building something that could age ex...
Most people searching for the next great retirement compounder go straight to the obvious names that are hot today: Nvidia , Microsoft , Meta . That's understandable. But the stocks that actually change lives over 20 or 30 years tend to be the ones nobody was talking about at the starting line. Right now, SoundHound AI (NASDAQ: SOUN) is one of the quieter names building something that could age extremely well. Image source: Getty Images. Continue reading
Nvidia’s new open source, quantum-focused AI models have pushed quantum computing stocks into the spotlight, and D-Wave Quantum (QBTS) is squarely in that conversation given its focus on quantum optimization. See our latest analysis for D-Wave Quantum. D-Wave’s latest move higher comes after a sharp 42.83% 7 day share price return and a 22.63% gain in the last session, even though the 90 day share...
Nvidia’s new open source, quantum-focused AI models have pushed quantum computing stocks into the spotlight, and D-Wave Quantum (QBTS) is squarely in that conversation given its focus on quantum optimization. See our latest analysis for D-Wave Quantum. D-Wave’s latest move higher comes after a sharp 42.83% 7 day share price return and a 22.63% gain in the last session, even though the 90 day share price return is a 27.54% decline, while the 1 year total shareholder return of 223.14% points to...
Stellantis Accelerates AI-led Strategy and Digital Transformation Through Strategic Collaboration with Microsoft to Enhance Customer Experiences Joint teams to co-develop more than 100 AI initiatives across sales, customer care and operations, driving innovation at a global scaleStellantis to strengthen global cyber defense center with AI‑driven analytics to help prevent cyberthreats and protect v...
Stellantis Accelerates AI-led Strategy and Digital Transformation Through Strategic Collaboration with Microsoft to Enhance Customer Experiences Joint teams to co-develop more than 100 AI initiatives across sales, customer care and operations, driving innovation at a global scaleStellantis to strengthen global cyber defense center with AI‑driven analytics to help prevent cyberthreats and protect vehicles, customers and operations worldwideScalable cloud modernization boosts agility, performance,
Prologis press release ( PLD ): Q1 FFO of $1.52 beats by $0.03 . Revenue of $2.3B (+7.5% Y/Y) beats by $180M . FY26 core FFO consensus of $6.13 2026 GUIDANCE Earnings (per diluted share) Previous Current Net earnings attributable to common stockholders $3.70 to $4.00 $3.80 to $4.05 Core FFO attributable to common stockholders/unitholders* $6.00 to $6.20 $6.07 to $6.23 Core FFO attributable to comm...
Prologis press release ( PLD ): Q1 FFO of $1.52 beats by $0.03 . Revenue of $2.3B (+7.5% Y/Y) beats by $180M . FY26 core FFO consensus of $6.13 2026 GUIDANCE Earnings (per diluted share) Previous Current Net earnings attributable to common stockholders $3.70 to $4.00 $3.80 to $4.05 Core FFO attributable to common stockholders/unitholders* $6.00 to $6.20 $6.07 to $6.23 Core FFO attributable to common stockholders/unitholders, excluding Net Promote Income (Expense)* $6.05 to $6.25 $6.12 to $6.28 Operations - Prologis Share Previous Current Average occupancy 94.75% to 95.75% 95.00% to 95.75% Cash Same Store NOI* 5.75% to 6.75% 6.25% to 7.00% Net Effective Same Store NOI* 4.25% to 5.25% 4.75% to 5.50% Strategic Capital (in millions) Previous Current Strategic Capital revenue, excluding promote revenue $650 to $670 $660 to $680 Net Promote Income (Expense)1 $(50) $(50) G&A (in millions) Previous Current General & administrative expenses $500 to $520 $510 to $525 Capital Deployment - Prologis Share (in millions)2 Previous Current Development stabilizations $2,250 to $2,750 $2,250 to $2,750 Development starts $3,000 to $4,000 $3,500 to $4,500 Acquisitions $1,000 to $1,500 $1,000 to $1,500 Contributions $1,500 to $2,000 $1,750 to $2,250 Dispositions $1,750 to $2,250 $1,750 to $2,250 Realized development gains $400 to $600 $500 to $700 Click to enlarge More on Prologis After A Massive Rally, The Easy Money May Be Gone - Prologis Prologis, Inc. (PLD) Presents at 47th Annual Raymond James Institutional Investor Conference Transcript Prologis, Inc. (PLD) Presents at Citi's Miami Global Property CEO Conference 2026 Transcript Prologis Q1 2026 Earnings Preview Prologis, La Caisse to create pan–European JV with ~€1B in seed assets
(RTTNews) - Eton Pharmaceuticals Inc. (ETON) on Thursday said it has appointed Judith M. Matthews as Executive Vice President, Accounting and Finance, effective immediately.
(RTTNews) - Eton Pharmaceuticals Inc. (ETON) on Thursday said it has appointed Judith M. Matthews as Executive Vice President, Accounting and Finance, effective immediately.